Insider Transactions in Q1 2025 at Ionis Pharmaceuticals Inc (IONS)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2025
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
38,843
-17.69%
|
$1,204,133
$31.65 P/Share
|
|
Feb 04
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
6,165
-9.69%
|
$191,115
$31.62 P/Share
|
|
Jan 31
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,327
-1.4%
|
$42,464
$32.46 P/Share
|
|
Jan 31
2025
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,406
-1.4%
|
$44,992
$32.4 P/Share
|
|
Jan 31
2025
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
1,523
-1.36%
|
$48,736
$32.44 P/Share
|
|
Jan 31
2025
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,242
-5.69%
|
$423,744
$32.45 P/Share
|
|
Jan 31
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
1,406
-2.16%
|
$44,992
$32.49 P/Share
|
|
Jan 31
2025
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
1,484
-2.37%
|
$47,488
$32.2 P/Share
|
|
Jan 31
2025
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
1,367
-2.77%
|
$43,744
$32.31 P/Share
|
|
Jan 30
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,607
+3.68%
|
-
|
|
Jan 30
2025
|
Richard S Geary EVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,820
+3.66%
|
-
|
|
Jan 30
2025
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,138
+3.56%
|
-
|
|
Jan 30
2025
|
Brett P Monia Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,372
+9.83%
|
-
|
|
Jan 30
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,820
+5.55%
|
-
|
|
Jan 30
2025
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
4,032
+6.06%
|
-
|
|
Jan 30
2025
|
Eric Swayze EVP Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,714
+6.99%
|
-
|
|
Jan 16
2025
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Indirect |
1,029
-25.1%
|
$32,928
$32.7 P/Share
|
|
Jan 16
2025
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,401
-11.97%
|
$108,832
$32.7 P/Share
|
|
Jan 16
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,752
-6.92%
|
$216,064
$32.9 P/Share
|
|
Jan 16
2025
|
Brian Birchler EVP, Corp and Development Ops |
SELL
Open market or private sale
|
Direct |
5,400
-8.93%
|
$172,800
$32.7 P/Share
|
|
Jan 16
2025
|
Shannon L. Devers EVP, Chief Human Resources Ofc |
SELL
Open market or private sale
|
Direct |
4,267
-21.12%
|
$136,544
$32.78 P/Share
|
|
Jan 16
2025
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
7,072
-6.82%
|
$226,304
$32.86 P/Share
|
|
Jan 16
2025
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
8,870
-7.6%
|
$283,840
$32.81 P/Share
|
|
Jan 16
2025
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
33,445
-13.89%
|
$1,070,240
$32.63 P/Share
|
|
Jan 16
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
7,360
-10.73%
|
$235,520
$32.83 P/Share
|
|
Jan 16
2025
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
6,523
-10.03%
|
$208,736
$32.79 P/Share
|
|
Jan 16
2025
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Indirect |
22
-10.68%
|
$704
$32.7 P/Share
|
|
Jan 16
2025
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
7,154
-13.54%
|
$228,928
$32.84 P/Share
|
|
Jan 15
2025
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,460
+37.5%
|
-
|
|
Jan 15
2025
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,787
+23.62%
|
-
|
|
Jan 15
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,011
+15.58%
|
-
|
|
Jan 15
2025
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
14,283
+19.11%
|
-
|
|
Jan 15
2025
|
Shannon L. Devers EVP, Chief Human Resources Ofc |
BUY
Exercise of conversion of derivative security
|
Direct |
12,295
+37.83%
|
-
|
|
Jan 15
2025
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,901
+15.41%
|
-
|
|
Jan 15
2025
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
23,887
+16.98%
|
-
|
|
Jan 15
2025
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
73,448
+23.37%
|
-
|
|
Jan 15
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,690
+22.31%
|
-
|
|
Jan 15
2025
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
17,372
+21.08%
|
-
|
|
Jan 15
2025
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Indirect |
49
+19.22%
|
-
|
|
Jan 15
2025
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
19,111
+26.57%
|
-
|
|
Jan 15
2025
|
Michael J. Yang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,931
+50.0%
|
-
|